semaglutide radnor Ro Is Prescribing Compounded Semaglutide, Despite Doctors' Warnings Semaglutide Weight Loss King of

Sources Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist (PMC) Application of nutrition interventions with GLP-1 based therapies: a narrative review (PMC) Endocrine Society: Consuming more protein may protect patients taking anti-obesity drug from muscle loss (ENDO 2025) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists (PMC) MedlinePlus: Fiber MedlinePlus: High-fiber foods Mayo Clinic Health System: Assessing protein needs Mayo Clinic: High-protein snacks Therapeutic Benefits and Dietary Restrictions of Fiber Intake (PMC)

This peptide can impact cytokine activity, one of the key drivers of inflammatory response and immune function

Enhanced insulin signaling following weight loss has been associated with decreased circulating levels of pro-inflammatory cytokines, including IL-6, TNF-, and C-reactive protein, as well as improvements in endothelial and adipose tissue function ( In inflammatory arthritis, including PsA, improved insulin sensitivity has been independently associated with reduced disease activity and inflammatory burden, even after adjustment for changes in BMI ( Consistent with this concept, GLP-1RAs have been shown to directly modulate immune responses by reducing the secretion of key pro-inflammatory cytokines such as IL-6 and TNF-, which are central drivers of inflammation in both PsO and PsA ( 3.4 Early PsA and future research directions Despite the promising metabolic and immunomodulatory effects observed in PsO, the role of GLP-1RAs in PsA, particularly in its early stages, remains largely unexplored

Heres the context: serious adverse events are rare and typically associated with pre-existing conditions